$18.55
+0.36
(+1.98%)▲
1.47%
Downside
Day's Volatility :2.26%
Upside
0.8%
34.12%
Downside
52 Weeks Volatility :34.16%
Upside
0.05%
Period | Innoviva, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 19.2% | 6.5% | 0.0% |
6 Months | 10.58% | 7.1% | 0.0% |
1 Year | 38.22% | 9.8% | 0.0% |
3 Years | 38.01% | 14.2% | -20.2% |
Market Capitalization | 1.1B |
Book Value | $11.21 |
Earnings Per Share (EPS) | 2.24 |
PE Ratio | 7.89 |
PEG Ratio | 0.24 |
Wall Street Target Price | 16.0 |
Profit Margin | 58.21% |
Operating Margin TTM | 33.3% |
Return On Assets TTM | 7.14% |
Return On Equity TTM | 28.67% |
Revenue TTM | 311.6M |
Revenue Per Share TTM | 4.85 |
Quarterly Revenue Growth YOY | 1.5% |
Gross Profit TTM | 276.1M |
EBITDA | 175.3M |
Diluted Eps TTM | 2.24 |
Quarterly Earnings Growth YOY | 0.1 |
EPS Estimate Current Year | 1.11 |
EPS Estimate Next Year | 1.01 |
EPS Estimate Current Quarter | 0.17 |
EPS Estimate Next Quarter | 0.22 |
What analysts predicted
Downside of 13.75%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 261.0M | ↑ 20.16% |
Net Income | 395.1M | ↑ 194.5% |
Net Profit Margin | 151.36% | ↑ 89.6% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 261.0M | ↑ 0.0% |
Net Income | 157.3M | ↓ 60.19% |
Net Profit Margin | 60.26% | ↓ 91.1% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 336.8M | ↑ 29.03% |
Net Income | 224.4M | ↑ 42.67% |
Net Profit Margin | 66.63% | ↑ 6.37% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 391.9M | ↑ 16.35% |
Net Income | 265.9M | ↑ 18.47% |
Net Profit Margin | 67.84% | ↑ 1.21% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 331.3M | ↓ 15.45% |
Net Income | 213.9M | ↓ 19.53% |
Net Profit Margin | 64.56% | ↓ 3.28% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 324.3M | ↓ 2.14% |
Net Income | 179.7M | ↓ 15.99% |
Net Profit Margin | 55.42% | ↓ 9.14% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 65.8M | ↓ 2.16% |
Net Income | -68.3M | ↓ 125.73% |
Net Profit Margin | -103.82% | ↓ 498.61% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 76.4M | ↑ 16.06% |
Net Income | 34.9M | ↓ 151.04% |
Net Profit Margin | 45.65% | ↑ 149.47% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 81.0M | ↑ 6.05% |
Net Income | 1.3M | ↓ 96.33% |
Net Profit Margin | 1.58% | ↓ 44.07% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 67.3M | ↓ 16.96% |
Net Income | 82.0M | ↑ 6309.84% |
Net Profit Margin | 121.99% | ↑ 120.41% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 89.3M | ↑ 32.73% |
Net Income | 61.5M | ↓ 25.0% |
Net Profit Margin | 68.93% | ↓ 53.06% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 81.0M | ↓ 9.32% |
Net Income | 36.5M | ↓ 40.63% |
Net Profit Margin | 45.13% | ↓ 23.8% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 548.2M | ↑ 49.23% |
Total Liabilities | 389.1M | ↓ 36.21% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 724.8M | ↑ 32.22% |
Total Liabilities | 382.7M | ↓ 1.65% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 999.6M | ↑ 37.9% |
Total Liabilities | 391.7M | ↑ 2.36% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 926.4M | ↓ 7.32% |
Total Liabilities | 400.5M | ↑ 2.23% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.2B | ↑ 32.93% |
Total Liabilities | 665.7M | ↑ 66.24% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.2B | ↑ 0.98% |
Total Liabilities | 568.6M | ↓ 14.59% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↓ 7.25% |
Total Liabilities | 665.7M | ↓ 3.01% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.1B | ↓ 8.26% |
Total Liabilities | 568.3M | ↓ 14.64% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.1B | ↓ 1.02% |
Total Liabilities | 563.2M | ↓ 0.9% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↑ 6.25% |
Total Liabilities | 560.6M | ↓ 0.45% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↑ 4.66% |
Total Liabilities | 568.6M | ↑ 1.42% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 1.3B | ↑ 1.94% |
Total Liabilities | 563.9M | ↓ 0.81% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 223.5M | ↑ 57.7% |
Investing Cash Flow | 3.5M | ↓ 115.14% |
Financing Cash Flow | -238.0M | ↑ 45.82% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 257.5M | ↑ 15.18% |
Investing Cash Flow | -18.0M | ↓ 611.59% |
Financing Cash Flow | -23.8M | ↓ 90.01% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 313.1M | ↑ 21.62% |
Investing Cash Flow | -314.9M | ↑ 1649.36% |
Financing Cash Flow | -29.8M | ↑ 25.27% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 363.8M | ↑ 16.19% |
Investing Cash Flow | 43.7M | ↓ 113.88% |
Financing Cash Flow | -452.5M | ↑ 1419.21% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 201.7M | ↓ 44.55% |
Investing Cash Flow | -56.6M | ↓ 229.53% |
Financing Cash Flow | -55.6M | ↓ 87.72% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 8.9M | ↓ 43.28% |
Investing Cash Flow | -8.7M | ↓ 108.88% |
Financing Cash Flow | -10.0M | ↓ 89.6% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 25.7M | ↑ 188.62% |
Investing Cash Flow | -35.7M | ↑ 311.64% |
Financing Cash Flow | -137.0M | ↑ 1269.48% |
Sell
Neutral
Buy
Innoviva, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Innoviva, Inc. | 11.73% | 10.58% | 38.22% | 38.01% | 58.59% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Innoviva, Inc. | 7.89 | 7.89 | 0.24 | 1.11 | 0.29 | 0.07 | NA | 11.21 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Innoviva, Inc. | Sell | $1.1B | 58.59% | 7.89 | 58.21% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Innoviva, Inc.
Revenue is down for the last 2 quarters, 89.27M → 80.95M (in $), with an average decrease of 9.3% per quarter
Netprofit is down for the last 3 quarters, 82.04M → 36.53M (in $), with an average decrease of 32.8% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 23.4%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 148.5%
BlackRock Inc
Sarissa Capital Management LP
Vanguard Group Inc
Franklin Resources Inc
Putnam Investments, LLC., a Franklin Templeton company
Dimensional Fund Advisors, Inc.
innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. innoviva's portfolio is anchored by the respiratory assets partnered with glaxo group limited (gsk), including relvar®/breo® ellipta® and anoro® ellipta®, which were jointly developed by innoviva and gsk. under the agreement with gsk, innoviva is eligible to receive associated royalty revenues from relvar®/breo® ellipta®, anoro® ellipta® and, if approved and commercialized, vi monotherapy, as well. in addition, innoviva retains a 15 percent economic interest in future payments made by gsk for earlier-stage programs partnered with theravance biopharma, inc. for more information, please visit innoviva's website at www.inva.com.
Organization | Innoviva, Inc. |
Employees | 112 |
CEO | Mr. Pavel Raifeld C.F.A. |
Industry | Health Technology |
A Spac I Acquisition Corp
$18.55
+1.98%
Keyarch Acquisition Corp
$18.55
+1.98%
Connexa Sports Technologies Inc
$18.55
+1.98%
Us Value Etf
$18.55
+1.98%
First Wave Biopharma Inc
$18.55
+1.98%
Global X Msci Next Emerging
$18.55
+1.98%
Fat Projects Acquisition Corp
$18.55
+1.98%
Capital Link Global Fintech
$18.55
+1.98%
Applied Uv Inc
$18.55
+1.98%